MedPath

广州大光制药有限公司

Ownership
-
Established
2009-07-09
Employees
-
Market Cap
-
Website
www.juyuanyy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

23

NMPA:23

Drug Approvals

Pranoprofen Eye Drops

Product Name
普拉洛芬滴眼液
Approval Number
国药准字H20254359
Approval Date
May 27, 2025
NMPA

Tolvaptan Orally Disintegrating Tablets

Product Name
托伐普坦口崩片
Approval Number
国药准字H20254195
Approval Date
May 20, 2025
NMPA

Tolvaptan Orally Disintegrating Tablets

Product Name
托伐普坦口崩片
Approval Number
国药准字H20254194
Approval Date
May 20, 2025
NMPA

Pheniramine Maleate Naphazoline Hydrochloride Eye Drops

Product Name
马来酸非尼拉敏盐酸萘甲唑啉滴眼液
Approval Number
国药准字H20253223
Approval Date
Jan 14, 2025
NMPA

Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution

Product Name
硫酸镁钠钾口服用浓溶液
Approval Number
国药准字H20249371
Approval Date
Nov 15, 2024
NMPA

Amisulpride Oral Solution

Product Name
氨磺必利口服溶液
Approval Number
国药准字H20244722
Approval Date
Aug 27, 2024
NMPA

Moxifloxacin Hydrochloride Eye Drops

Product Name
盐酸莫西沙星滴眼液
Approval Number
国药准字H20233863
Approval Date
Jun 30, 2023
NMPA

Pregabalin Oral Solution

Product Name
普瑞巴林口服溶液
Approval Number
国药准字H20233752
Approval Date
Jun 21, 2023
NMPA

Levofloxacin Eye Drops

Product Name
左氧氟沙星滴眼液
Approval Number
国药准字H20233723
Approval Date
Jun 14, 2023
NMPA

Entecavir Oral Solution

Product Name
恩替卡韦口服溶液
Approval Number
国药准字H20223829
Approval Date
Nov 8, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.